Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.
Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.
Osoyoos cannabis has acquired a psilocybin-focuse biopharma company based in Jamaica.
An amalgamation of two private companies as psychedelics company Mindset Pharma Inc prepares to go public.
Cybin Corp will become the latest psychedelics company to go public, via RTO.
Psychedelic drugs are an emerging sector with exciting investment potential. Here are some tips on beginning your due diligence.
Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
Champignon Brands has added a new contact research organization (CRO) to advance its IP portfolio.
MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.
AlphaMind Brands Inc is entering the functional mushrooms market.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now